Journal: BMJ Open

Article Title: Patients’ experiences regarding self-monitoring of the disease course: an observational pilot study in patients with inflammatory rheumatic diseases at a rheumatology outpatient clinic in The Netherlands

doi: 10.1136/bmjopen-2019-033321

Figure Lengend Snippet: Follow-up duration in days of the 47 iMonitor participants. Y-axis: 47 patients who participated in the self-monitoring program, each line represents a patient; X-axis: days since start of study (different start days possible for patients).

Article Snippet: Self-monitoring program iMonitor, the online self-monitoring program tested in this study, was developed by Pfizer.

Techniques:

Journal: European Journal of Medical Research

Article Title: Evaluation of self-sampling-based cervical cancer screening strategy using HPV Selfy CE-IVD test coupled with home-collection kit: a clinical study in Italy

doi: 10.1186/s40001-023-01263-8

Figure Lengend Snippet: Genotyping performed by HPV Selfy in the study cohort

Article Snippet: At the time of the present study, only two CE-IVD assays reported self-sampling in their intended use: (a) HPV Selfy, validated for self-collection since May 2019 on a large population of more than 1,000 women [ , ]; data of clinical trials performed between 2018 and 2019 were recently published and showed clinical validation of the HPV Selfy assay for primary cervical cancer screening purposes according to Meijer’s guidelines and for self-collection based screening program according to requirements indicated in the VALHUDES protocol [ , ]; and (b) HPV-Risk, developed by SelfScreen and distributed by QIAGEN with the commercial name of “QIAScreen”; its intended use for self-collection was applied in August 2019 and it was validated for self-collection on a very limited sample size [ , ]; the assay was validated for primary cervical cancer screening purposes, according to Meijer’s guidelines, but it was not, and it is still not, validated according for cervical cancer primary screening on self-collected samples, according to VALHUDES protocol [ ].

Techniques:

Journal: European Journal of Medical Research

Article Title: Evaluation of self-sampling-based cervical cancer screening strategy using HPV Selfy CE-IVD test coupled with home-collection kit: a clinical study in Italy

doi: 10.1186/s40001-023-01263-8

Figure Lengend Snippet: Comparison between HPV Selfy and cobas ® 4800 HPV in the study cohort ( n = 395)

Article Snippet: At the time of the present study, only two CE-IVD assays reported self-sampling in their intended use: (a) HPV Selfy, validated for self-collection since May 2019 on a large population of more than 1,000 women [ , ]; data of clinical trials performed between 2018 and 2019 were recently published and showed clinical validation of the HPV Selfy assay for primary cervical cancer screening purposes according to Meijer’s guidelines and for self-collection based screening program according to requirements indicated in the VALHUDES protocol [ , ]; and (b) HPV-Risk, developed by SelfScreen and distributed by QIAGEN with the commercial name of “QIAScreen”; its intended use for self-collection was applied in August 2019 and it was validated for self-collection on a very limited sample size [ , ]; the assay was validated for primary cervical cancer screening purposes, according to Meijer’s guidelines, but it was not, and it is still not, validated according for cervical cancer primary screening on self-collected samples, according to VALHUDES protocol [ ].

Techniques: Comparison

Journal: European Journal of Medical Research

Article Title: Evaluation of self-sampling-based cervical cancer screening strategy using HPV Selfy CE-IVD test coupled with home-collection kit: a clinical study in Italy

doi: 10.1186/s40001-023-01263-8

Figure Lengend Snippet: Comparison between HPV Selfy and cobas ® 4800 HPV in the LSIL subpopulation ( n = 8)

Article Snippet: At the time of the present study, only two CE-IVD assays reported self-sampling in their intended use: (a) HPV Selfy, validated for self-collection since May 2019 on a large population of more than 1,000 women [ , ]; data of clinical trials performed between 2018 and 2019 were recently published and showed clinical validation of the HPV Selfy assay for primary cervical cancer screening purposes according to Meijer’s guidelines and for self-collection based screening program according to requirements indicated in the VALHUDES protocol [ , ]; and (b) HPV-Risk, developed by SelfScreen and distributed by QIAGEN with the commercial name of “QIAScreen”; its intended use for self-collection was applied in August 2019 and it was validated for self-collection on a very limited sample size [ , ]; the assay was validated for primary cervical cancer screening purposes, according to Meijer’s guidelines, but it was not, and it is still not, validated according for cervical cancer primary screening on self-collected samples, according to VALHUDES protocol [ ].

Techniques: Comparison